DOP2019000020A - Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 - Google Patents

Compuestos de tiazolo-piridina sustituida como inhibidores de malt1

Info

Publication number
DOP2019000020A
DOP2019000020A DO2019000020A DO2019000020A DOP2019000020A DO P2019000020 A DOP2019000020 A DO P2019000020A DO 2019000020 A DO2019000020 A DO 2019000020A DO 2019000020 A DO2019000020 A DO 2019000020A DO P2019000020 A DOP2019000020 A DO P2019000020A
Authority
DO
Dominican Republic
Prior art keywords
malt1
inhibitors
tiazolo
pyridine compounds
compounds replaced
Prior art date
Application number
DO2019000020A
Other languages
English (en)
Inventor
Sinha Neelima
P Palle Venkata
Kukreja Gagan
Rangnath Jagdale Arun
Keruji Deshmukh Gokul
Popatrao Vyavahare Vinod
Chandrashekhar Kulkarni Kiran
Rao Irlapati Nageswara
Kumar Kamboj Rajender
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of DOP2019000020A publication Critical patent/DOP2019000020A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos de fórmula general (I), en la que R1-R3 son como se definen en el presente documento, para su uso como inhibidores de MALT1 en el tratamiento de enfermedades o trastornos autoinmunes e inflamatorios. También se describen métodos para sintetizar los compuestos. También se describen composiciones farmacéuticas que contienen un compuesto de la invención y un método para tratar un paciente por una enfermedad o trastorno autoinmune o inflamatorio, por ejemplo, un cáncer, administrando un compuesto de la invención.
DO2019000020A 2016-07-29 2019-01-28 Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 DOP2019000020A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201621026107 2016-07-29

Publications (1)

Publication Number Publication Date
DOP2019000020A true DOP2019000020A (es) 2019-04-30

Family

ID=59745317

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2019000020A DOP2019000020A (es) 2016-07-29 2019-01-28 Compuestos de tiazolo-piridina sustituida como inhibidores de malt1

Country Status (15)

Country Link
US (1) US20190275012A9 (es)
JP (1) JP2019522035A (es)
KR (1) KR20190033607A (es)
CN (1) CN110312724A (es)
AU (1) AU2017302182B2 (es)
CA (1) CA3032334A1 (es)
CL (1) CL2019000221A1 (es)
DO (1) DOP2019000020A (es)
IL (1) IL289474A (es)
MX (1) MX2019001132A (es)
PE (1) PE20190656A1 (es)
PH (1) PH12019500214A1 (es)
RU (1) RU2019104890A (es)
SG (1) SG11201900745VA (es)
WO (1) WO2018020474A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11248007B2 (en) 2017-03-08 2022-02-15 Cornell University Inhibitors of MALT1 and uses thereof
WO2019099307A1 (en) * 2017-11-17 2019-05-23 Hepagene Therapeutics, Inc. Urea derivatives as inhibitors of ask1
US10888550B2 (en) * 2018-06-18 2021-01-12 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
KR20210024548A (ko) * 2018-06-18 2021-03-05 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피라졸 유도체
CN109265453A (zh) * 2018-10-23 2019-01-25 华侨大学 一种用作caspase-3激活剂的缩氨基脲类衍生物及其应用
JP6972384B2 (ja) 2018-11-28 2021-11-24 武田薬品工業株式会社 複素環化合物
MX2021012417A (es) 2019-04-11 2021-11-12 Janssen Pharmaceutica Nv Anillos de piridina que contienen derivados como inhibidores de malt1.
TW202115077A (zh) * 2019-07-01 2021-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｍａｌｔ１抑制劑及其用途
WO2021063735A1 (en) * 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives
KR20220123023A (ko) * 2019-12-27 2022-09-05 슈뢰딩거, 인크. 시클릭 화합물 및 이의 사용 방법
US20230192685A1 (en) 2020-05-27 2023-06-22 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
WO2021262969A1 (en) 2020-06-24 2021-12-30 The General Hospital Corporation Materials and methods of treating cancer
WO2022101676A1 (en) * 2020-11-12 2022-05-19 Monopteros Therapeutics,Inc. Materials and methods of treating cancer
WO2023148501A1 (en) 2022-02-03 2023-08-10 C4X Discovery Limited Heterocyclic derivatives as malt1 inhibitors
WO2023192506A1 (en) * 2022-03-31 2023-10-05 Rarified Biosciences, Inc. Malt1 modulators and uses thereof
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
IL149145A0 (en) * 1999-11-05 2002-11-10 Warner Lambert Co Prevention of plaque rupture by acat inhibitors
AU2003222667A1 (en) * 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
US9051595B2 (en) 2007-06-01 2015-06-09 University Of Lausanne Malt1 specific cleavage in assay and screening method
EP2222326B2 (en) 2007-11-21 2015-02-25 Vib Vzw Inhibitors of malt1 proteolytic activity and uses thereof
EP2736899A1 (en) * 2011-07-26 2014-06-04 Grünenthal GmbH Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands
PT2739285T (pt) 2011-08-02 2019-03-26 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Inibição seletiva da protease malt1 por meio de derivados de fenotiazina
WO2013053765A1 (en) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
EP2916656B1 (en) 2012-11-09 2017-10-25 Cornell University Small molecule inhibitors of malt1
WO2014086478A1 (en) 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
EP3013818B1 (en) 2013-06-26 2021-12-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (s)-enantiomer of mepazine as paracaspase (malt1) inhibitor for treating cancer
EP3097124B1 (en) 2014-01-21 2018-12-19 Helmholtz Zentrum München Means and methods for detecting activated malt1
PT3149001T (pt) * 2014-05-28 2019-07-25 Novartis Ag Novos derivados de pirazolee pirimidina e seu uso como inibidores de malt1
DE102015210224A1 (de) 2015-06-02 2016-12-08 Universitätsklinikum Hamburg-Eppendorf Neuer wirkstoff zur behandlung von krebs
WO2017040304A1 (en) 2015-08-28 2017-03-09 Cornell University Malt1 inhibitors and uses thereof
WO2017057695A1 (ja) 2015-09-30 2017-04-06 東レ株式会社 ジフェニルピラゾール誘導体及びその医薬用途
US20200289514A1 (en) 2015-11-13 2020-09-17 Novartis Ag Novel Pyrazolo Pyrimidine Derivatives
US11248007B2 (en) * 2017-03-08 2022-02-15 Cornell University Inhibitors of MALT1 and uses thereof

Also Published As

Publication number Publication date
RU2019104890A3 (es) 2020-08-31
US20190275012A9 (en) 2019-09-12
PE20190656A1 (es) 2019-05-08
AU2017302182B2 (en) 2021-11-04
KR20190033607A (ko) 2019-03-29
SG11201900745VA (en) 2019-02-27
MX2019001132A (es) 2019-12-16
RU2019104890A (ru) 2020-08-31
CA3032334A1 (en) 2018-02-01
JP2019522035A (ja) 2019-08-08
CL2019000221A1 (es) 2019-06-07
PH12019500214A1 (en) 2019-10-28
CN110312724A (zh) 2019-10-08
IL289474A (en) 2022-02-01
AU2017302182A1 (en) 2019-03-07
WO2018020474A1 (en) 2018-02-01
US20190160045A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CY1121850T1 (el) Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CO2017011484A2 (es) Inhibidores de bromodominio
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
CL2018002924A1 (es) Inhibidores de bromodominios
GT201600123A (es) Inhibidores de syk
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
CL2019002240A1 (es) Dendrímeros terapéuticos.
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
CY1122763T1 (el) Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
CL2019000661A1 (es) Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica.
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias